HK1210209A1 - Treatment of diseases of endothelial dysfunction and inflammation - Google Patents

Treatment of diseases of endothelial dysfunction and inflammation

Info

Publication number: HK1210209A1
Authority: HK; Hong Kong
Prior art keywords: inflammation; diseases; treatment; endothelial dysfunction; dysfunction
Prior art date: 2012-12-12

Application number

HK15110737.0A

Other languages

English (en)

Chinese (zh)

Inventor

Wayne Gregory Kimpton

Simon Reeves Bailey

Silviu Itescu

Peter Ghosh

Original Assignee

Mesoblast Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-12-12

Filing date

2015-10-29

Publication date

2016-04-15

2015-10-29 Application filed by Mesoblast Inc filed Critical Mesoblast Inc

2016-04-15 Publication of HK1210209A1 publication Critical patent/HK1210209A1/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Developmental Biology & Embryology (AREA)
Immunology (AREA)
Cardiology (AREA)
Cell Biology (AREA)
Zoology (AREA)
Biotechnology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
Epidemiology (AREA)
Rheumatology (AREA)
Virology (AREA)
Biochemistry (AREA)
Microbiology (AREA)
General Engineering & Computer Science (AREA)
Urology & Nephrology (AREA)
Diabetes (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Dermatology (AREA)
Molecular Biology (AREA)
Emergency Medicine (AREA)
Obesity (AREA)

HK15110737.0A 2012-12-12 2015-10-29 Treatment of diseases of endothelial dysfunction and inflammation HK1210209A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201261736361P	2012-12-12	2012-12-12
PCT/AU2013/001452 WO2014089623A1 (en)	2012-12-12	2013-12-12	Treatment of diseases of endothelial dysfunction and inflammation

Publications (1)

Publication Number	Publication Date
HK1210209A1 true HK1210209A1 (en)	2016-04-15

Family

ID=50933585

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HK15110737.0A HK1210209A1 (en)	2012-12-12	2015-10-29	Treatment of diseases of endothelial dysfunction and inflammation

Country Status (12)

Country	Link
US (2)	US20160175360A1 (xx)
EP (2)	EP3556850A1 (xx)
JP (5)	JP6572130B2 (xx)
KR (3)	KR102506612B1 (xx)
CN (2)	CN105358163B (xx)
AU (4)	AU2013360024B2 (xx)
CA (1)	CA2893942C (xx)
ES (1)	ES2742035T3 (xx)
HK (1)	HK1210209A1 (xx)
IL (1)	IL239308A0 (xx)
SG (2)	SG10201705061RA (xx)
WO (1)	WO2014089623A1 (xx)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20110014701A1 (en)	2007-12-04	2011-01-20	Proteobioactives Pty Ltd.	Protection of Progenitor Cells and Regulation of Their Differentiation
WO2022114111A1 (ja) *	2020-11-27	2022-06-02	マルホ株式会社	医薬品又は化粧品用組成物

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5139941A (en)	1985-10-31	1992-08-18	University Of Florida Research Foundation, Inc.	AAV transduction vectors
AU8200191A (en)	1990-07-09	1992-02-04	United States of America, as represented by the Secretary, U.S. Department of Commerce, The	High efficiency packaging of mutant adeno-associated virus using amber suppressions
US5173414A (en)	1990-10-30	1992-12-22	Applied Immune Sciences, Inc.	Production of recombinant adeno-associated virus vectors
AU663725B2 (en)	1991-08-20	1995-10-19	United States Of America, Represented By The Secretary, Department Of Health And Human Services, The	Adenovirus mediated transfer of genes to the gastrointestinal tract
EP2305235A1 (en)	1997-04-02	2011-04-06	The Brigham And Women's Hospital, Inc.	Means of ascertaining an individual's risk profile for atherosclerotic disease
AUPQ147799A0 (en)	1999-07-07	1999-07-29	Medvet Science Pty. Ltd.	Mesenchymal precursor cell
AU2003901668A0 (en)	2003-03-28	2003-05-01	Medvet Science Pty. Ltd.	Non-haemopoietic precursor cells
DE19939781C2 (de)	1999-08-21	2003-06-18	Schott Glas	Skulltiegel für das Erschmelzen oder das Läutern von anorganischen Substanzen, insbesondere von Gläsern und Glaskeramiken
US20080095749A1 (en) *	2004-03-22	2008-04-24	Sudeepta Aggarwal	Mesenchymal stem cells and uses therefor
WO2006032092A1 (en)	2004-09-24	2006-03-30	Angioblast Systems, Inc.	Multipotential expanded mesenchymal precursor cell progeny (memp) and uses thereof
EP3327116A1 (en)	2005-04-12	2018-05-30	Mesoblast, Inc.	Isolation of adult multipotential cells by tissue non-specific alkaline phosphatase
CA2608048A1 (en) *	2005-05-10	2006-11-16	United States Of America Department Of Veteran's Affairs	Therapy of kidney diseases and multiorgan failure with mesenchymal stem cells and mesenchymal stem cell conditioned media
US20080260703A1 (en) *	2007-04-23	2008-10-23	Medistem Labortories	Treatment of Insulin Resistance and Diabetes
WO2009073616A2 (en) *	2007-11-30	2009-06-11	New York Medical College	Compositions comprising vascular and myocyte progenitor cells and methods of their use
AU2008334036B2 (en) *	2007-11-30	2014-05-29	New York Medical College	Methods of reducing transplant rejection and cardiac allograft vasculopathy by implanting autologous stem cells
US20110014701A1 (en) *	2007-12-04	2011-01-20	Proteobioactives Pty Ltd.	Protection of Progenitor Cells and Regulation of Their Differentiation
EP2294184A4 (en) *	2008-06-30	2013-03-06	Mesoblast Inc	TREATMENT OF EYE DISEASES AND EXCESSIVE NEOVASCULARIZATION WITH THE HELP OF COMBINED THERAPY
CN103800370B (zh) *	2008-11-20	2017-10-24	中胚有限公司	用于治疗胰功能异常的方法
WO2010138180A2 (en) *	2009-05-26	2010-12-02	The University Of Vermont And State Agriculture College	Compositions and methods for cardiac tissue repair
WO2011073521A1 (en) *	2009-12-15	2011-06-23	Petri Salven	Methods for enriching adult-derived endothelial progenitor cells and uses thereof
WO2012047733A2 (en) *	2010-09-29	2012-04-12	Aidan Research And Consulting, Llc.	Treatment of acne by conditioned media
US9405700B2 (en)	2010-11-04	2016-08-02	Sonics, Inc.	Methods and apparatus for virtualization in an integrated circuit
US10206951B2 (en) *	2011-06-03	2019-02-19	Mesoblast, Inc.	Methods of treating multiple sclerosis using STRO-1+ and TNAP+ multipotential cells
ES2763381T3 (es)	2011-07-04	2020-05-28	Mesoblast Inc	Procedimientos de tratamiento o prevención de enfermedades reumáticas
US10071123B2 (en) *	2012-08-01	2018-09-11	United Therapeutics Corporation	Treatment of pulmonary arterial hypertension with mesenchymal stem cells
EP3415150B1 (en) *	2013-01-09	2021-08-18	United Therapeutics Corporation	Treatment of vasculopathy with prostacyclin and mesenchymal stem cells

2013
- 2013-12-12 KR KR1020227005920A patent/KR102506612B1/ko active Active
- 2013-12-12 AU AU2013360024A patent/AU2013360024B2/en active Active
- 2013-12-12 WO PCT/AU2013/001452 patent/WO2014089623A1/en active Application Filing
- 2013-12-12 ES ES13862555T patent/ES2742035T3/es active Active
- 2013-12-12 EP EP19174698.1A patent/EP3556850A1/en active Pending
- 2013-12-12 KR KR1020157017531A patent/KR102217962B1/ko active Active
- 2013-12-12 KR KR1020217004422A patent/KR102367981B1/ko active Active
- 2013-12-12 SG SG10201705061RA patent/SG10201705061RA/en unknown
- 2013-12-12 CA CA2893942A patent/CA2893942C/en active Active
- 2013-12-12 CN CN201380072732.5A patent/CN105358163B/zh active Active
- 2013-12-12 JP JP2015546770A patent/JP6572130B2/ja active Active
- 2013-12-12 US US14/650,172 patent/US20160175360A1/en not_active Abandoned
- 2013-12-12 SG SG11201504340YA patent/SG11201504340YA/en unknown
- 2013-12-12 CN CN202010796960.9A patent/CN111840329B/zh active Active
- 2013-12-12 EP EP13862555.3A patent/EP2931876B1/en active Active
2015
- 2015-06-09 IL IL239308A patent/IL239308A0/en unknown
- 2015-10-29 HK HK15110737.0A patent/HK1210209A1/xx unknown
2019
- 2019-04-29 AU AU2019202960A patent/AU2019202960B2/en active Active
- 2019-07-01 JP JP2019123243A patent/JP6829288B2/ja active Active
2021
- 2021-01-21 JP JP2021008250A patent/JP7201715B2/ja active Active
- 2021-10-12 AU AU2021250848A patent/AU2021250848A1/en not_active Abandoned
2022
- 2022-12-22 JP JP2022206042A patent/JP2023030116A/ja active Pending
2023
- 2023-10-04 US US18/481,041 patent/US20240115618A1/en active Pending
2024
- 2024-07-11 JP JP2024111736A patent/JP2024147655A/ja active Pending
- 2024-10-10 AU AU2024227208A patent/AU2024227208A1/en active Pending

Also Published As

Publication number	Publication date
KR102367981B1 (ko)	2022-02-25
AU2013360024A1 (en)	2015-07-02
EP2931876A4 (en)	2016-05-25
KR20210021104A (ko)	2021-02-24
CN111840329A (zh)	2020-10-30
AU2019202960A1 (en)	2019-05-16
US20240115618A1 (en)	2024-04-11
JP2021073240A (ja)	2021-05-13
JP2024147655A (ja)	2024-10-16
JP6829288B2 (ja)	2021-02-10
CN105358163B (zh)	2020-09-11
SG10201705061RA (en)	2017-07-28
US20160175360A1 (en)	2016-06-23
CN111840329B (zh)	2024-10-15
EP2931876A1 (en)	2015-10-21
KR20150093732A (ko)	2015-08-18
IL239308A0 (en)	2015-07-30
JP6572130B2 (ja)	2019-09-04
KR102217962B1 (ko)	2021-02-22
JP7201715B2 (ja)	2023-01-10
AU2021250848A1 (en)	2021-11-04
EP3556850A1 (en)	2019-10-23
AU2019202960B2 (en)	2021-07-29
CA2893942A1 (en)	2014-06-19
JP2016504311A (ja)	2016-02-12
CN105358163A (zh)	2016-02-24
JP2019214571A (ja)	2019-12-19
JP2023030116A (ja)	2023-03-07
KR102506612B1 (ko)	2023-03-06
ES2742035T3 (es)	2020-02-12
SG11201504340YA (en)	2015-07-30
CA2893942C (en)	2023-03-28
AU2013360024B2 (en)	2019-02-28
KR20220029758A (ko)	2022-03-08
WO2014089623A1 (en)	2014-06-19
AU2024227208A1 (en)	2024-10-31
EP2931876B1 (en)	2019-05-29

Publication	Publication Date	Title
IL239368A0 (en)	2015-07-30	Sparing–ppar thiazolidinediones and combinations for the treatment of neurodegenerative diseases of the nervous system
HK1203942A1 (en)	2015-11-06	Therapeutically active compounds and their methods of use
HK1211474A1 (en)	2016-05-27	Treatment of immune-related and inflammatory diseases
HK1204319A1 (en)	2015-11-13	Therapeutically active compounds and their methods of use
HK1198631A1 (en)	2015-05-22	Prevention and treatment of ocular conditions
HK1198439A1 (en)	2015-04-24	Therapeutically active compounds and their methods of use
EP2670434A4 (en)	2015-11-11	TREATMENT OF TAUOPATHIA
HK1199015A1 (en)	2015-06-19	Treatment of inflammation
EP2723347A4 (en)	2015-02-25	PREVENTING AND TREATING INFLAMMATORY DISEASES
HK1206623A1 (en)	2016-01-15	Pharmaceutical compositions and treatment of mastitis
HK1220352A1 (zh)	2017-05-05	和神經變性疾病的治療
HK1204573A1 (en)	2015-11-27	Treatment of inflammatory skin disorders
HK1211213A1 (en)	2016-05-20	Treatment of diseases involving mucin
HK1209639A1 (en)	2016-04-08	Gpbp-1 inhibition and its therapeutic use gpbp-1
HK1213175A1 (zh)	2016-06-30	介導的疾病和/或病症的治療和/或預防
HK1203430A1 (en)	2015-10-30	Bisarylsulfonamides useful in the treatment of inflammation and cancer
ZA201401800B (en)	2015-07-29	Novel plant defensins and use in the treatment of proliferative diseases
HK1210209A1 (en)	2016-04-15	Treatment of diseases of endothelial dysfunction and inflammation
HK1198121A1 (en)	2015-03-13	Therapeutic combinations of netupitant and palonosetron
GB201100651D0 (en)	2011-03-02	Treatment of inflammation
AU2012900272A0 (en)	2012-02-16	Treatment and inhibition of corneal erosions
GB201201779D0 (en)	2012-03-14	Treatment of inflammatory disorders